JP6245981B2 - 含水有機溶媒中の18f−標識化トレーサーの合成 - Google Patents
含水有機溶媒中の18f−標識化トレーサーの合成 Download PDFInfo
- Publication number
- JP6245981B2 JP6245981B2 JP2013503976A JP2013503976A JP6245981B2 JP 6245981 B2 JP6245981 B2 JP 6245981B2 JP 2013503976 A JP2013503976 A JP 2013503976A JP 2013503976 A JP2013503976 A JP 2013503976A JP 6245981 B2 JP6245981 B2 JP 6245981B2
- Authority
- JP
- Japan
- Prior art keywords
- solvent
- water
- labeling
- labeled
- fluoride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003960 organic solvent Substances 0.000 title claims description 18
- 230000015572 biosynthetic process Effects 0.000 title description 16
- 238000003786 synthesis reaction Methods 0.000 title description 16
- 239000000700 radioactive tracer Substances 0.000 title description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 238000002372 labelling Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 31
- 239000000523 sample Substances 0.000 claims description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 239000002243 precursor Substances 0.000 claims description 13
- 238000005349 anion exchange Methods 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 10
- 239000003444 phase transfer catalyst Substances 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 6
- 239000003586 protic polar solvent Substances 0.000 claims description 5
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 3
- HKVLOZLUWWLDFP-UHFFFAOYSA-M hydron;tetrabutylazanium;carbonate Chemical compound OC([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC HKVLOZLUWWLDFP-UHFFFAOYSA-M 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 claims description 2
- XWIJIXWOZCRYEL-UHFFFAOYSA-M potassium;methanesulfonate Chemical compound [K+].CS([O-])(=O)=O XWIJIXWOZCRYEL-UHFFFAOYSA-M 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003880 polar aprotic solvent Substances 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 description 27
- 238000001035 drying Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- 238000003682 fluorination reaction Methods 0.000 description 11
- 238000004809 thin layer chromatography Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000012043 crude product Substances 0.000 description 7
- 238000000163 radioactive labelling Methods 0.000 description 7
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- -1 potassium crown ether Chemical class 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 239000003957 anion exchange resin Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 150000002222 fluorine compounds Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 2
- ZSSPATINHRVRTN-LMANFOLPSA-N 3-fluoranyl-2-[4-[(2-nitroimidazol-1-yl)methyl]triazol-1-yl]propan-1-ol Chemical compound N1=NN(C(C[18F])CO)C=C1CN1C([N+]([O-])=O)=NC=C1 ZSSPATINHRVRTN-LMANFOLPSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- OIBDVHSTOUGZTJ-PEBLQZBPSA-N [(2r,3r,4s,5s,6s)-3,4,6-triacetyloxy-5-(trifluoromethylsulfonyloxy)oxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@@H](OS(=O)(=O)C(F)(F)F)[C@@H](OC(C)=O)[C@@H]1OC(C)=O OIBDVHSTOUGZTJ-PEBLQZBPSA-N 0.000 description 2
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000002608 ionic liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- LPZSRGRDVVGMMX-FJBGPTLJSA-N (2s,3s,4s,5s)-2-(fluoranylmethyl)-5-(2-nitroimidazol-1-yl)oxolane-3,4-diol Chemical compound O1[C@H](C[18F])[C@@H](O)[C@H](O)[C@H]1N1C([N+]([O-])=O)=NC=C1 LPZSRGRDVVGMMX-FJBGPTLJSA-N 0.000 description 1
- LPZSRGRDVVGMMX-JWXFUTCRSA-N (2s,3s,4s,5s)-2-(fluoromethyl)-5-(2-nitroimidazol-1-yl)oxolane-3,4-diol Chemical compound O1[C@H](CF)[C@@H](O)[C@H](O)[C@H]1N1C([N+]([O-])=O)=NC=C1 LPZSRGRDVVGMMX-JWXFUTCRSA-N 0.000 description 1
- MKXBOPXRKXGSTI-LTDRGYAJSA-N 1-[(2S,4S,5R)-2-(18F)fluoranyl-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound [18F][C@@]1(C[C@H](O)[C@@H](CO)O1)N1C(=O)NC(=O)C(C)=C1 MKXBOPXRKXGSTI-LTDRGYAJSA-N 0.000 description 1
- LAZLFOJNNMFIGO-KTXUZGJCSA-N 1-azido-2-fluoranylethane Chemical compound [18F]CCN=[N+]=[N-] LAZLFOJNNMFIGO-KTXUZGJCSA-N 0.000 description 1
- HIIJZYSUEJYLMX-JZRMKITLSA-N 1-fluoranyl-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound [18F]CC(O)CN1C=CN=C1[N+]([O-])=O HIIJZYSUEJYLMX-JZRMKITLSA-N 0.000 description 1
- CEIVUGLBKBWVAE-UHFFFAOYSA-N 2-amino-9-[3-(fluoromethyl)-4-hydroxybutyl]-3h-purin-6-one Chemical compound O=C1NC(N)=NC2=C1N=CN2CCC(CO)CF CEIVUGLBKBWVAE-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-M 4-bromobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-M 0.000 description 1
- SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
- PTJWIQPHWPFNBW-FTFTVQOISA-N 5-[(3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidine-2,4-dione Chemical compound C1([C@@H](O)[C@H](O)[C@H](O1)CO)C=1C(NC(NC=1)=O)=O PTJWIQPHWPFNBW-FTFTVQOISA-N 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical group OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003608 radiolysis reaction Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K51/0448—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil tropane or nortropane groups, e.g. cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K51/047—Benzodiazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
これらの従来の標識化方式において、数ミリリットルの18O−水から痕跡量の18Fフッ化物がアニオン交換カラムに捕捉される。この後、前記18F−フッ化物イオンは、水に溶解した、K2CO3のような、塩を使用することにより、アニオン交換カラムから溶離される。無水アセトニトリルに溶解したカリウムクラウンエーテルクリプトフィックス(Kryptofix)K222のような添加物を、K2CO3水溶液とともに使用して18F−フッ化物の溶離を促進してもよく、又は、所望により、K2CO3による溶離後に反応容器に添加してもよい。
溶離工程後、試薬K2CO3及びクリプトフィックスK222がアセトニトリルの高含水溶液に溶解しているので、徹底的な乾燥方式が必要である。この乾燥工程により、K2CO3、クリプトフィックスK222及び18F−フッ化物の活性化された混合物が生じる。乾燥プロセスは、高められた温度で、しばしば、反応容器からの水の蒸発を助けるために減圧下に、共沸混合物を蒸発させることから始まる。この最初の乾燥は、乾燥の効率によるが、完了するのに最大30分要する。最初の蒸発の後、18F−フッ化物が標識化に満足すべき程度に水分を含まないようにするために、十分な量の水を効果的に除去すべく更に蒸発を行なうことが必要となる可能性がある。
毒性についての情報が知られていない化合物を用いるこれらのタイプの溶離については、注射又は造影に先立って、最終生成物中のこれらの添加物の分析が要求されると思われ、これにより、製造ワークフローが決定的に複雑なものになる。
本発明において、18F−標識化は、長々とした乾燥工程を用いることなく、水の量を厳密に制御して、高収率で起きる。より具体的には、少なくとも一種の有機溶媒中に所定量の水を溶解した溶媒を用いて、a)アニオン交換樹脂から18F−フッ化物を溶離し、そして、b)18F−フッ素化を、18F−フッ化物を乾燥させることなく、少なくとも一種の標識化試薬及び少なくとも一種の相転移触媒の存在下に、実施する。適切であれば、いかなる標識化試薬及び相転移触媒をも使用することができる。
適切な標識化試薬の例としては、K2CO3、KHCO3、Cs2CO3、メシル酸カリウム、シュウ酸カリウム及び重炭酸テトラブチルアンモニウムが挙げられる。適切な相転移触媒の例としては、クリプトフィックスK222が挙げられる。
有機溶媒としては、例えば、アセトニトリル、ジメチルスルホキシド(「DMSO」)、テトラヒドロフラン(「THF」)、ジメチルホルムアミド(「DMF」)、N−メチルピロリドン(「NMP」)及びジオキサン並びにその他の、極性非プロトン性溶媒が挙げられる。有機溶媒としては、また、例えば、t−BuOH及びt−アミルアルコール並びにその他の、極性プロトン性溶媒が挙げられる。
Claims (10)
- 所定量の水及び少なくとも一種の有機溶媒を含有してなる第一の溶媒を調製するステップと、前記第一の溶媒で、或る量の18Fを、アニオン交換カートリッジから、溶離して0.1%〜5.0%の範囲の合計水量を有する18F−フッ化物の溶液を調製するステップとからなる溶離工程;及び
前記18F−フッ化物の溶液を用いて、少なくとも一種の標識化試薬及び少なくとも一種の相間移動触媒の存在下で、プローブ前駆体の18F−標識化を行なって18F−標識化プローブを生成させる18F−標識化工程;を備えてなる、18F−標識化プローブを合成する方法であって、
前記18F−標識化工程が、前記18F−フッ化物の溶液をプローブ前駆体と合一する工程、並びに、前記18F−フッ化物の溶液及び前記プローブ前駆体が合一されたときに、前記18F−標識化溶液の合計水量が0.1%〜2.0%の範囲内になるように、前記18F−フッ化物の溶液及び前記プローブ前駆体の少なくとも一方を有機溶媒で希釈する工程を、備えるものであり、
前記溶離工程及び前記18F−標識化工程において水分除去操作を行なわない方法。 - 前記第一の溶媒が、更に、前記少なくとも一種の標識化試薬及び前記少なくとも一種の相間移動触媒を含有してなるものである請求項1に記載の方法。
- 前記少なくとも一種の標識化試薬が、K2CO3、KHCO3,Cs2CO3、メシル酸カリウム、シュウ酸カリウム及び重炭酸テトラブチルアンモニウムからなる群から選ばれるものである、請求項1に記載の方法。
- 前記少なくとも一種の相間移動触媒がクリプトフィックスK222(登録商標)である請求項1に記載の方法。
- 前記有機溶媒が極性非プロトン性溶媒を含有するものである請求項1に記載の方法。
- 前記極性非プロトン性溶媒が、アセトニトリル、ジメチルスルホキシド(「DMSO」)、テトラヒドロフラン(「THF」)、ジメチルホルムアミド(「DMF」)、N−メチルピロリドン(「NMP」)及びジオキサンからなる群から選ばれるものである請求項5に記載の方法。
- 前記有機溶媒が極性プロトン性溶媒を含有するものである請求項1に記載の方法。
- 前記極性プロトン性溶媒がtBuOH及びt−アミルアルコールからなる群から選ばれるものである請求項7に記載の方法。
- 前記生成された18F−標識化プローブが18F−FDG、18F−HX4、18F−FLT、18F−MISO、18F−FAZA、18F−ファリプライド、18F−FHBG、18F−FHPG、18F−4−フルオロベンズアルデヒド、18F−4−フルオロエチルベンゾエート、18F−フルオロメチルベンゾエート、18F−フルオロエチルアジド及び18F−W372からなる群から選ばれるものである請求項1に記載の方法。
- 前記生成された18F−標識化プローブが18F−VM4−037である請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32207410P | 2010-04-08 | 2010-04-08 | |
US61/322,074 | 2010-04-08 | ||
PCT/US2011/031681 WO2011127345A1 (en) | 2010-04-08 | 2011-04-08 | Synthesis of 18f-labeled tracers in hydrous organic solvents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013529186A JP2013529186A (ja) | 2013-07-18 |
JP6245981B2 true JP6245981B2 (ja) | 2017-12-13 |
Family
ID=43980750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013503976A Expired - Fee Related JP6245981B2 (ja) | 2010-04-08 | 2011-04-08 | 含水有機溶媒中の18f−標識化トレーサーの合成 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9023316B2 (ja) |
EP (1) | EP2556372A1 (ja) |
JP (1) | JP6245981B2 (ja) |
KR (1) | KR101430422B1 (ja) |
CA (1) | CA2795762C (ja) |
WO (1) | WO2011127345A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10639608B2 (en) | 2010-04-08 | 2020-05-05 | Siemens Medical Solutions Usa, Inc. | System, device and method for preparing tracers and transferring materials during radiosynthesis |
WO2011127345A1 (en) | 2010-04-08 | 2011-10-13 | Siemens Medical Solutions Usa, Inc. | Synthesis of 18f-labeled tracers in hydrous organic solvents |
GB201120586D0 (en) * | 2011-11-30 | 2012-01-11 | Ge Healthcare Ltd | Solid phase extraction neutralisation |
KR101326000B1 (ko) * | 2012-01-30 | 2013-11-07 | 재단법인 아산사회복지재단 | 수소이온 농도가 조절된 플루오린-18의 용리액 제조 및 이를 이용한 플루오린-18의 표지방법 |
AU2015253843A1 (en) * | 2014-04-29 | 2016-10-20 | Biosearch Technologies, Inc. | Compounds compositions and methods including thermally labile moieties |
NL2014828B1 (en) | 2015-05-20 | 2017-01-31 | Out And Out Chemistry S P R L | Method of performing a plurality of synthesis processes of preparing a radiopharmaceutical in series, a device and cassette for performing this method. |
US11242314B2 (en) | 2016-01-11 | 2022-02-08 | Washington University | Synthesizing pet tracers using [F-18]sulfonyl fluoride as a source of [F-18]fluoride |
US11707538B2 (en) | 2016-01-11 | 2023-07-25 | Washington University | Methods and devices to generate [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides |
DK3538161T3 (da) * | 2016-11-08 | 2022-09-05 | Univ California | Fremgangsmåder til flerdosissyntese af [F-18]FDDNP til kliniske indstillinger |
KR101842989B1 (ko) * | 2018-01-02 | 2018-03-28 | (주)퓨쳐켐 | 카보닐기를 갖는 알코올 용매를 이용한 플루오르화 화합물의 제조방법 |
WO2024163546A1 (en) | 2023-02-02 | 2024-08-08 | Eli Lilly And Company | Novel compounds for tau imaging |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4606908A (en) | 1983-10-04 | 1986-08-19 | Washington Research Foundation | Methods and compositions for plasma and organ imaging |
JPH05247082A (ja) * | 1992-03-06 | 1993-09-24 | Japan Tobacco Inc | 2’−フルオロ−2’,3’−ジデオキシヌクレオシドの製造方法及び中間体 |
US5264570A (en) | 1992-08-05 | 1993-11-23 | General Electric Company | Method for making 2-[18 F]fluoro-2-deoxy-D-glucose |
WO1994021653A1 (en) | 1993-03-22 | 1994-09-29 | General Electric Company | Method for making 2-fluoro-2-deoxyglucose |
US5425063A (en) | 1993-04-05 | 1995-06-13 | Associated Universities, Inc. | Method for selective recovery of PET-usable quantities of [18 F] fluoride and [13 N] nitrate/nitrite from a single irradiation of low-enriched [18 O] water |
US5932178A (en) | 1996-03-29 | 1999-08-03 | Nkk Plant Engineering Corporation | FDG synthesizer using columns |
GB0115927D0 (en) | 2001-06-29 | 2001-08-22 | Nycomed Amersham Plc | Solid-phase nucleophilic fluorination |
KR100431657B1 (ko) | 2001-09-25 | 2004-05-17 | 삼성전자주식회사 | 웨이퍼의 처리 방법 및 처리 장치, 그리고 웨이퍼의 식각방법 및 식각 장치 |
US7160637B2 (en) | 2003-05-27 | 2007-01-09 | The Regents Of The University Of California | Implantable, miniaturized microbial fuel cell |
US7160537B2 (en) | 2003-12-15 | 2007-01-09 | Siemens Medical Solutions Usa, Inc. | Method for preparing radiolabeled thymidine having low chromophoric byproducts |
US7022872B2 (en) | 2003-12-19 | 2006-04-04 | Molecular Technologies, Inc. | Method for making fluorine labeled L-Dopa |
GB0407952D0 (en) | 2004-04-08 | 2004-05-12 | Amersham Plc | Fluoridation method |
GB0425501D0 (en) * | 2004-11-19 | 2004-12-22 | Amersham Plc | Fluoridation process |
KR100789847B1 (ko) | 2004-12-15 | 2007-12-28 | (주)퓨쳐켐 | 알코올 용매하에서 유기플루오로 화합물의 제조방법 |
CN101346392A (zh) * | 2005-12-06 | 2009-01-14 | 日本医事物理股份有限公司 | 放射性氟标记化合物的制备方法 |
US7731940B2 (en) * | 2006-01-25 | 2010-06-08 | The Regents Of The University Of California | Compositions and methods related to serotonin 5-HT1A receptors |
CN100560548C (zh) | 2006-06-01 | 2009-11-18 | 郭启勇 | 采用离子液体作为相转移催化剂合成18f标记正电子放射性示踪剂的方法 |
WO2008082695A2 (en) | 2006-07-18 | 2008-07-10 | Board Of Regents Of The University Of Nebraska | Methods and agents for preparing 18f-radiolabeled fluorinating agents |
AU2007294685B2 (en) | 2006-09-15 | 2012-06-07 | Siemens Medical Solutions Usa, Inc. | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins |
EP1916003A1 (en) | 2006-10-25 | 2008-04-30 | Bayer Schering Pharma Aktiengesellschaft | Thymidine analogs for imaging |
EP2017359A3 (en) | 2007-06-11 | 2009-08-05 | Trasis S.A. | Method for the elution of 18F fluoride trapped on an anion-exchange resin in a form suitable for efficient radiolabeling without any evaporation step |
US7928210B2 (en) | 2007-03-01 | 2011-04-19 | Siemens Medical Solutions Usa, Inc. | Nucleoside based proliferation imaging markers |
JP2010523599A (ja) * | 2007-04-05 | 2010-07-15 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | クリックケミストリーを使用した炭酸脱水酵素−ixのための分子イメージングプローブの開発 |
CA2683433C (en) | 2007-04-05 | 2016-10-11 | Siemens Medical Solutions Usa, Inc. | Nitro-imidazole hypoxia imaging agents |
US8071035B2 (en) | 2007-04-12 | 2011-12-06 | Siemens Medical Solutions Usa, Inc. | Microfluidic radiosynthesis system for positron emission tomography biomarkers |
EP1990310A1 (en) | 2007-04-23 | 2008-11-12 | Trasis S.A. | Method for the preparation of reactive 18F fluoride, and for the labeling of radiotracers, using a modified non-ionic solid support and without any evaporation step |
EP2062630A1 (en) | 2007-11-20 | 2009-05-27 | Trasis S.A. | Method for the direct elution of reactive 18F fluoride from an anion exchange resin in an organic medium by the use of strong organic bases |
EP2214722A1 (en) | 2007-11-07 | 2010-08-11 | GE Healthcare BV | Stabilization of radiopharmaceuticals |
EP2279011B1 (en) | 2008-04-30 | 2017-10-25 | Siemens Medical Solutions USA, Inc. | Substrate based pet imaging agents |
EP2297070A2 (en) * | 2008-07-03 | 2011-03-23 | Bayer Schering Pharma Aktiengesellschaft | Compounds and processes for production of radiopharmaceuticals |
US20110184159A1 (en) * | 2008-07-07 | 2011-07-28 | Bayer Schering Pharma Aktiengesellschaft | Process for production of radiopharmaceuticals |
US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
EP2411057B1 (en) | 2009-03-23 | 2020-05-06 | Eli Lilly and Company | Imaging agents for detecting neurological disorders |
US8435454B2 (en) | 2009-07-09 | 2013-05-07 | Siemens Medical Solutions Usa, Inc. | Modular system for radiosynthesis with multi-run capabilities and reduced risk of radiation exposure |
US8273300B2 (en) | 2009-07-09 | 2012-09-25 | Siemens Medical Solutions Usa, Inc. | Modular system for radiosynthesis with multi-run capabilities and reduced risk of radiation exposure |
WO2011127345A1 (en) | 2010-04-08 | 2011-10-13 | Siemens Medical Solutions Usa, Inc. | Synthesis of 18f-labeled tracers in hydrous organic solvents |
-
2011
- 2011-04-08 WO PCT/US2011/031681 patent/WO2011127345A1/en active Application Filing
- 2011-04-08 EP EP11715812A patent/EP2556372A1/en not_active Withdrawn
- 2011-04-08 JP JP2013503976A patent/JP6245981B2/ja not_active Expired - Fee Related
- 2011-04-08 CA CA2795762A patent/CA2795762C/en active Active
- 2011-04-08 US US13/634,708 patent/US9023316B2/en active Active
- 2011-04-08 KR KR1020127029268A patent/KR101430422B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP2556372A1 (en) | 2013-02-13 |
JP2013529186A (ja) | 2013-07-18 |
KR101430422B1 (ko) | 2014-08-14 |
WO2011127345A1 (en) | 2011-10-13 |
US20130005956A1 (en) | 2013-01-03 |
CA2795762C (en) | 2017-03-28 |
CA2795762A1 (en) | 2011-10-13 |
US9023316B2 (en) | 2015-05-05 |
KR20130024913A (ko) | 2013-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6245981B2 (ja) | 含水有機溶媒中の18f−標識化トレーサーの合成 | |
DK2799091T3 (en) | System, device and method for the preparation of tracers and transfer of materials during radiosynthesis | |
Cai et al. | Chemistry with [18F] fluoride ion | |
Banister et al. | Fluorine-18 chemistry for PET: a concise introduction | |
JP6145107B2 (ja) | 加水分解性脱保護工程及び固相抽出を含む18f−標識化合物の生産 | |
Kim et al. | Rapid synthesis of [18F] FDG without an evaporation step using an ionic liquid | |
Inkster et al. | A non-anhydrous, minimally basic protocol for the simplification of nucleophilic 18F-fluorination chemistry | |
Bratteby et al. | Aliphatic 18F‐Radiofluorination: Recent Advances in the Labeling of Base‐Sensitive Substrates | |
Zhang et al. | One‐step synthesis of 4‐[18F] fluorobenzyltriphenylphosphonium cation for imaging with positron emission tomography | |
US20130022525A1 (en) | Methods and compositions for drying in the preparation of radiopharmaceuticals | |
EP1944281A1 (en) | 18F-labeled compounds, method for the preparation and use thereof | |
Roberts et al. | Radiosynthesis and ‘click’conjugation of ethynyl‐4‐[18F] fluorobenzene—an improved [18F] synthon for indirect radiolabeling | |
KR101605291B1 (ko) | 유기 플루오르화 지방족 화합물의 제조방법 및 정제방법 | |
US10052395B1 (en) | [18F] fluoride cryptate complexes for radiolabeling fluorinations | |
US20200047158A1 (en) | Solid phase conditioning | |
AU2015343906B2 (en) | Method for preparing organic fluoride-aliphatic compound and method for purifying organic fluoride-aliphatic compound | |
US10308664B2 (en) | [18F] fluoride cryptate complexes for radiolabeling fluorinations | |
Kovac et al. | 18F-Labeled aryl-tracers through direct introduction of [18F] fluoride into electron-rich arenes | |
JP7159157B2 (ja) | 放射性フッ素標識化合物の製造方法および放射性医薬の製造方法 | |
US10633396B2 (en) | [18F] fluoride cryptate complexes for radiolabeling fluorinations | |
Vallabhajosula | Radiohalogens for Molecular Imaging (Fluorine and Iodine) | |
Cocevska | Optimization of reaction conditions for synthesis of [18F] FMISO using stable [19F] F | |
JP2020034493A (ja) | 放射性核種18fの精製方法 | |
Kilbourn et al. | Fluorine-18 radiopharmaceuticals | |
Miller IV | Selective Iodination Using Diaryliodonium Salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140408 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140606 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140901 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150611 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20151110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160322 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170823 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6245981 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |